4-Methoxypyridine

We are 4-Methoxypyridine CAS:620-08-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Methoxypyridine
CAS.NO:620-08-6
Synonyms:METHYL PYRIDIN-4-YL ETHER; 
4-methoxypridine; 4-methoxyPyr; 
Pyridine,4-methoxy; 4-methoxyridine;
Molecular Formula:C6H7NO
Molecular Weight:109.12600
 
Physical and Chemical Properties:
Density:1.075;
Melting point:4oC;
Boiling point:191oC;
Flash point:74oC;
Index of Refraction:1.518-1.522;
 
Specification:
Appearance:Colourless to yellow clear liquid
Purity(GC):≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis

4-Methoxypyridine


Related News: The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.2260-00-6 From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.26115-70-8 Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.4-Methylthiazole-5-carboxaldehyde In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
5-Fluoropicolinic acid View Details
(S)-Methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate View Details
5-Chloro-1-Pentanol View Details
Ethyl trifluoropyruvate Cas:13081-18-0 manufacturer (Chloromethyl)triethoxysilane manufacturer Phenylboronic acid manufacturer 2-methyl-2-(methylsulfanyl)propanaldoxime manufacturer Potassium hexacyanocobaltate manufacturer